"As Devonian progresses rapidly within its pharmaceutical programme, the time has come to expand the Board of Directors to ensure the corporation achieves its goals," said Dr André P. Boulet, President and Chief Executive Officer of the corporation.
"Devonian's Board of Directors is extremely pleased to be welcoming Mr Jacques Bernier and Dr Louis Flamand as directors of the corporation. They bring with them a wealth of preclinical and pharmaceutical experience that enhances the bench strength of the Board of Directors."
From 2008 until 2014, Mr Bernier was CEO of Folia Biotech Inc., a clinical stage biopharmaceutical corporation focused on exploiting its proprietary immune-therapeutic platform to bring to market therapeutic products in oncology and certain infectious diseases.
During his tenure, he has concluded several business partnerships that have strengthened the development of Folia's technology.
Prior to joining Folia, Mr Bernier acquired a broad management experience as the owner of a group of pharmacies and as a member of the Board of Directors of various pharmaceutical corporations. He has a profound understanding of the pharmaceutical industry and an acute experience in business development.
Dr Flamand is a full professor and vice-chair of the department of microbiology-infectious-disease-immunology at the Faculty of Medicine, Université Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research centre.
Before joining Laval University, Dr Flamand obtained his PhD at the University of Montreal and post-doctoral training at the National Institutes of Health and at the Institute of Human Virology (Maryland, USA).
He received his MBA in pharmaceutical management from Université Laval. He is president of the biohazards risk committee at Université Laval. He is also member of the HHV-6 Foundation scientific advisory board since 2006.
Dr Flamand has experience in preclinical development. Throughout his career, Dr Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology.
Dr Flamand is the author of more than 80 peer-reviewed publications and is lead editor of the book Human Herpes Viruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management, 3rd Edition.
The corporation also announced that as of 30 May 2017, Mr François Michaud will not be acting as Chief Financial Officer of the corporation. Ms Colette Laurin, the Corporate's Corporate Controller, will assume Mr Michaud's responsibilities as the corporation's interim Chief Financial Officer.
The corporation also announces Mr Matt Peppler has resigned as a member of the corporation's Board of Directors.
Dr André P. Boulet commented: "On behalf of the management team and the Devonian's Board of Directors, I would like to thank Matt and François for their contribution to Devonian during the last 2 years."
